Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 354-360

  Neovius, Martin ^a   Arkema, E V ^a   Olsson, H ^a   Eriksson, J K ^a   Kristensen, L E ^b   Simard, J F ^a   Askling, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGE; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; GENDER; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INCIDENCE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TIME TO TREATMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY;

ADALIMUMAB; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921329367     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204128     Document Type: Article

References (30)

1. Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
2. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229-34.
3. Hyrich KL, Watson KD, Lunt M, et al. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50:117-23.
4. Simard JF, Arkema EV, Sundstrom A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford) 2011;50:204-13.
5. Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012;71:382-5.
6. Kievit W, Fransen J, Adang EM, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50:196-203.
7. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
8. Flendrie M, Creemers MC, Welsing PM, et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii30-3.
9. Hjardem E, Hetland ML, Ostergaard M, et al. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005;64:1220-3.
10. Hetland ML, Lindegaard HM, Hansen A, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
11. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;67:37-42.
12. Yazici Y, Krasnokutsky S, Barnes JP, et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13.
13. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
14. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
15. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 2009;1173:837-46.
16. Brocq O, Roux CH, Albert C, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54.
17. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
18. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
19. Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-8.
20. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42.
21. Neovius M, Sundstrom A, Simard J, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011;40:8-15.
22. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
23. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
24. Neovius M, Simard J, Sundstrom A, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011;70:516-19.
25. Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006;22:185-98.
26. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
27. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
28. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
29. Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64:3850-5.
30. Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73:595-9.